A. Jong

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

F. Hoogen, W. Laan, A. Broeder, 2018, Arthritis & rheumatology.

Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial

F. Kraaimaat, A. Evers, P. Riel, 2002, Pain.

Recurrent and migratory reflex sympathetic dystrophy syndrome

P. Barrera, P. Riel, L. Putte, 1992, Clinical Rheumatology.

Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.

L. V. D. van de Putte, P. V. van Riel, L. Putte, 1997, British journal of rheumatology.

Cognitive–behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions

M Effting, F. Kraaimaat, P. V. van Riel, 2006, Annals of the rheumatic diseases.